We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Spinal Fluid Tests Differentiate Concurrent Brain Diseases

By LabMedica International staff writers
Posted on 10 May 2012
Alzheimer's disease (AD) can be distinguished from frontotemporal lobar degeneration (FTLD) by looking at the levels of two specific biomarkers in the spinal fluid. More...


By using different platforms and assaying the concentration of a neuronal protein and peptide amino acids in cerebral spinal fluid (CSF) it is possible to make a definitive differentiation between the two brain diseases.

Scientists at the University of Pennsylvania (Philadelphia, PA, USA) studied 142 neuropathologically diagnosed neurodegenerative dementia patients, including 71 with AD, 29 with FTLD, three with amyotrophic lateral sclerosis, seven with dementia with Lewy bodies, and 32 with mixed diagnosis. For 136 patients there was enzyme linked immunosorbent assay (ELISA) CSF data for comparison to 43 controls and for 110 patients there was Luminex CSF data for comparison with 46 controls. Amyloid beta (Aβ42), total, and phosphorylated tau181 were measured.

The investigators determined that values from the two platforms could effectively be transformed into equivalent units, and these values accurately distinguished AD from FTLD. A cutoff of 0.34 for the t-tau: Aβ1-42 ratio had 90% to 100% sensitivity and 91% to 96.7% specificity to differentiate FTLD cases, respectively. Clinical and neuropathological diagnoses showed an 81.3% overall agreement. ELISA and Luminex showed high sensitivity and specificity to classify AD subjects against FTLD subjects and controls and moderate sensitivity and specificity for classifying FTLD subjects against controls. The ELISA platform revealed 69.4% and the Luminex (Austin, TX, USA) platform 96.4% of the cases with mixed neuropathological diagnoses including a diagnosis AD (which was 24.8% of the sample), were classified as AD. Probabilities obtained by models based on clinical and neuropathological diagnoses differed and underestimated the true diagnostic accuracy.

John Q. Trojanowski, MD, PhD, professor of Pathology and Laboratory Medicine and co-director of the Center for Neurodegenerative Disease Research, said, "With the emergence of disease-modifying treatments for AD and other neurodegenerative diseases, it will be of utmost importance to accurately identify the underlying neuropathology in patients." Murray Grossman, MD, professor of Neurology, and senior author of the study added, "We need to develop better CSF diagnostic panels for the early diagnosis of neurodegenerative dementias, including those due to mixed neurodegenerative disease pathologies that commonly co-occur with Alzheimer's." The studies were presented at the American Academy of Neurology's 64th Annual Meeting, held April 21 to April 28, 2012, in New Orleans (LA, USA).

Related Links:

University of Pennsylvania
Luminex



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.